Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
CANTON, Mass., March 10, 2016 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Tuesday, March 15, 2016 at 7:30 a.m. ET. The Company will discuss its financial results for 2015 and provide a corporate update.
Conference Call Information:
To access the conference call, please dial (866) 864-3220 (U.S.) or (704) 908-0478 (International). An audio webcast will be accessible from the Investor Relations section of the Company’s website: http://www.collegiumpharma.com/. An archived webcast will be available on the Company’s website approximately two hours after the event.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
Contact: Douglas Carlson Vice President, Corporate Development [email protected]
